We are dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases by advancing the science of epigenetics. Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world we’re trying to build by developing our innovative family of simple, easy to use, cost-effective tests. Our patented technologies use chromosomal structures such as nucleosomes and transcription factors as biomarkers in cancer and other diseases. All the tests in our portfolio detect various characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment. Our ground breaking nucleosome quantification technology is currently being used for cancer applications in veterinary medicine and we are continuing to expand our technology in human medicine through early clinical trials in cancer, sepsis and beyond. Regarding our Nu.Q® technology, we have four pillars of focus: Nu.Q® Vet, Nu.Q® NETs, Nu.Q® Discover and Nu.Q® Cancer. We have also developed Capture-PCR™, a novel method for liquid biopsy enabling rapid, cost-effective cancer detection in a routine blood test. We are headquartered in Henderson, Nevada with locations in Belgium, California, Singapore and the UK. We are listed on the New York Stock Exchange (NYSE AMERICAN) as VolitionRX Limited (VNRX).